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Hereditary spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of neurodegenerative
disorders for which 14 different genetic loci have been identified. In some SCA types, expanded tri- or penta-
nucleotide repeats have been identified, and the length of these expansions correlates with the age at onset and
with the severity of the clinical phenotype. In several other SCA types, no genetic defect has yet been identified.
We describe a large, three-generation family with early-onset tremor, dyskinesia, and slowly progressive cerebellar
ataxia, not associated with any of the known SCA loci, and a mutation in the fibroblast growth factor 14 (FGF14)
gene on chromosome 13q34. Our observations are in accordance with the occurrence of ataxia and paroxysmal
dyskinesia in Fgf14-knockout mice. As indicated by protein modeling, the amino acid change from phenylalanine
to serine at position 145 is predicted to reduce the stability of the protein. The present FGF14 mutation represents
a novel gene defect involved in the neurodegeneration of cerebellum and basal ganglia.
Spinocerebellar ataxias (SCAs) are a growing group of
hereditary neurodegenerative diseases for which 14
different genetic loci have been identified. An expansion
of an unstable trinucleotide repeat in the coding or non-
coding region has been found for nine different SCA
types (Holmes et al.1999; Koob et al. 1999; Zoghbi et
al. 1999; Nakamura et al. 2001), whereas a pentanu-
cleotide repeat expansion has been found in SCA10
(MIM 603516) (Matsuura et al. 2000). Anticipation has
been described in several SCA types (Nakamura et al.
2001). Although ataxia is the unifying clinical charac-
teristic, other noncerebellar symptoms, such as dopa-
mine-responsive parkinsonism, early-onset tremor, or
epilepsy, may develop early or late in a specific SCA type
(Gwinn-Hardy et al. 2000; O’Hearn et al 2001; Ras-
mussen et al. 2001).
We describe a large, four-generation white family of
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Dutch descent with an autosomal dominant cerebellar
ataxia slowly progressing over decades, in which the
known candidate genes involved in other SCA types did
not show a repeat expansion. The proband of this family
was a 45-year-old woman (individual III:9 in fig. 1) who
was referred for tremor and progressive ataxia. She re-
ported that her 69-year-old father had severe ataxia,
whereas her 24-year-old daughter complained of tremor
and mild unsteadiness. Testing for trinucleotide-repeat
expansions in SCA1, SCA2, SCA3, SCA6, SCA7, and
DRPLA (MIM 164400, 183090, 109150, 183086,
164500, and 125370) of the proband gave results in the
normal population range.
Twenty-one members of this three-generation family
were examined by two neurologists. Ataxia, tremor, or
both was seen in 14 members (7 men and 7 women) and
transmitted as an autosomal dominant trait (fig. 1). In-
dividual III:1 was not willing to participate in the study,
although by family report he was considered to be af-
fected. We could neither perform neurological exami-
nation of this patient nor obtain blood for DNA iso-
lation. For the 21 family members examined, themedical
records and, if available, hard copies of structural brain
imaging were reviewed. Two patients underwent nerve
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Table 1
Clinical Phenotype of 14 Affected Family Members with Early-Onset Tremor and Cerebellar Ataxia
INDIVIDUAL
AGE (IN YEARS) AT RESULT OF NEUROLOGICAL EXAMINATIONa
IMAGING
FINDINGExamination
Onset of
Ataxiab W P N D T LA GA
II:3 79 30 WC A  U   Unable NA
II:5 71 34 WC Dp  U   Unable Cerebellar atrophy
II:7 69 27 C       Cerebellar atrophy
II:12 64 40 ff       Normalc
II:13 61 30 f       NA
III:4 54 40 f       Normal
III:5 31 30 f A      NA
III:6 30  Normal A      NA
III:7 27  Normal A      Normal
III:9 48 28 f       Normal
III:11 42 37 f       Normal
III:14 43 40 f       Normal
III:16 39  f A      NA
IV:1 24  Normal Dp      Normal
a A p aggressive outbursts; C p walking with a cane; D p dysarthria; Dp p treated for depression; GA p gait
ataxia; LA p limb ataxia; N p gaze-evoked nystagmus; NA p not available; P p psychiatric episodes; T p tre-
mor; U p unintelligible speech; W p walking; WC p wheelchair; f p mild unsteadiness; ff p impaired walking;
 p present or mild;  p absent;  p moderate; unable p unable to walk without assistance.
b Age at onset of gait ataxia was estimated retrospectively by patient.
c CT scan of the brain at age 60 years.
conduction studies, and five patients were evaluated by
means of a battery of neuropsychological tests. Clinical
data for the 14 affected family members are summarized
in table 1. The age at examination was 48.8 17.9
years (range 24–79 years). All had noticed trembling of
both hands since childhood; the trembling was exacer-
bated by emotional stress and physical exercise. Patients
first experienced mild unsteadiness and ataxia of upper
limbs, especially under unusual circumstances, at age
15–20 years. The age at onset of gait ataxia was ret-
rospectively determined by rough estimation based on
the extremely slow progression of the disease process.
Historical data showed no indication of anticipation in
consecutive generations. Six patients did not complete
primary education, and only 4 of the 14 patients at-
tended secondary school. Aggressive outbursts were
mentioned in five patients and depression in three pa-
tients. Neurological examination showed dysmetric sac-
cades, disrupted ocular pursuit movements, gaze-evoked
nystagmus, cerebellar dysarthria, and a high-frequency,
small-amplitude tremor in both hands in most of the
patients. Six patients showed head tremor, and subtle
orofacial dyskinesias were seen in eight patients. Severe
limb and gait ataxia was present in the three oldest pa-
tients. One at-risk individual (III:1, age 48 years), with
known chronic alcohol abuse, showed a gaze-evoked
nystagmus, although he did not have tremor, dyskinesia,
or ataxia. Further neurological examination was unre-
markable except for brisk knee jerks and diminished
vibration sense at ankles in several patients. Neuro-
psychological testing showed low IQ scores (four pa-
tients) and impairment of memory functions (three pa-
tients), abstract thinking (three patients), and word
fluency (one patient).
Moderate cerebellar atrophy on structural imaging
was seen in two patients (fig. 2), whereas findings were
normal in seven other patients. The individual with
chronic alcoholism showed generalized cerebral atrophy.
Imaging of dopamine-D2 receptors, using [123I]iodo-
benzamide single-photon-emission computed tomog-
raphy (IBZM-SPECT), in one patient (II:7) showed a
reduced dopamine D2-receptor binding of the left
striatum. Normal binding ratios in striatum of the same
patient were found on iodine-123-N-fluoropropyl-2b-
carbomethoxy-3b-(4-iodophenyl) nortropane (FP-CIT)
SPECT. Nerve conduction studies revealed mild axonal
polyneuropathy on electromyography in both patients
examined (II:7 and II:12).
After approval by the medical ethics committee of the
ErasmusMedical Center, Rotterdam, genomic DNAwas
isolated from peripheral blood from all 14 affecteds, 4
spouses, and 7 at-risk individuals, as described elsewhere
(Miller et al. 1988). We performed a systematic genome
screen, using STRs from the ABI PRISM Linkage Map-
ping Set MD-10 (Applied Biosystems). Additional mark-
ers for fine mapping were obtained from Ge´ne´thon and
from the Center for Medical Genetics (Marshfield Med-
ical Research Foundation) genetic marker sets. Marker
order and distances were obtained from the Marshfield
integrated linkage map. Markers were amplified accord-
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Figure 2 MRI of the brain of patient II:7 showed atrophy of
cerebellar hemispheres (T1-weighted axial images).
Table 2
Primer Sequences and Amplified Product Sizes
Exon
Forward
5′r3′
Reverse
5′r3′
Size
(bp)
1a agggcgagccacggtctg gagggaaggagcctggagaa 373
1b aatcactgagaagtctcaaag ctgcagatctagctcgatga 362
2 gcctgtttctgtggcttact aactatgtaactggtggcctga 357
3 tattgtcgcatcagcccttc ttgttgttgctgccattgtt 423
4 gtatatccggtcctccatgc tccagcactttgtgaaggtt 428
5 ctctgtgggctggaaatga agcaggaatgtctggtgagg 388
ing to methods specified by the manufacturers. PCR
products were loaded on an ABI 3100 automated se-
quencer (filter set D), and the data were analyzed with
ABI GeneMapper (version 2.0) software.
Two-point linkage analysis was performed with the
MLINK program of the LINKAGE package (version
5.1) (Lathrop and Lalouel 1984). Maximum LOD and
location scores were calculated for each marker, assum-
ing ataxia to be an autosomal dominant disorder with
90% penetrance and with a gene frequency of 1:10,000;
no phenocopies were allowed, and equal allele frequen-
cies of the genotyped markers were used in the calcu-
lations. Individuals with unknown clinical status (ques-
tion marks in fig. 1) were regarded as unknown in the
linkage analysis. We obtained positive LOD scores for
adjacent markers on chromosome 13q34 (D13S158,
D13S173, and D13S1265). Further refinement of this
region by saturation with additional markers confirmed
these findings, and two-point linkage analysis yielded a
maximum LOD score of at recombinationZp 4.28
fraction 0 for marker D13S280. Changing allele fre-
quencies of the polymorphic markers did not signifi-
cantly alter LOD and location scores. Subsequently, hap-
lotypes for 11 adjacent markers on chromosome 13q34
were then constructed by parsimony (fig. 1), and several
recombinants that defined the limits of the ataxia-sus-
ceptibility region were detected. The recombination
events in affected individuals demonstrate that the re-
gion is limited by marker D13S779 on the centromeric
side (individuals II:12, III:14, and III:16) and by marker
D13S796 on the telomeric side (individual III:4), show-
ing the critical region to be 10.6 cM on the sex-averaged
linkage map. The SCA8 locus could be excluded by test-
ing the following markers flanking the SCA8 locus
(MIM 603680) on chromosome 13q21: D13S1309,
D13S1268, D13S275, D13S1296, D13S279, and
D13S18. SCA8 CTG-repeat length was determined by
radioactive PCR essentially as described by Weber and
May (1989) and was within the normal range for af-
fected and unaffected family members (data not shown)
(Koob et al. 1999).
According to Ensembl and the Human Genome
Browser, within this critical region, 10 genes with a
known function and 58 predicted transcripts with un-
known function are located, including fibroblast growth
factor 14 (FGF14) or fibroblast growth factor homol-
ogous factor 4 (FHF4) (MIM 601515). A recently pub-
lished mouse model lacking Fgf14 showed ataxia and
paroxysmal dyskinesia (Wang et al. 2002). This led us
to begin our candidate-gene mutation analysis with the
FGF14 gene in this family. The FGF14 gene encompasses
∼200 kb on the genomic level. Two major mRNA tran-
scripts are produced, FGF14a and FGF14b, which differ
in the definition of exon 1 (Wang et al. 2000). The two
transcripts encode protein isoforms of 247 and 252
amino acids, respectively. For mutation analysis, the ge-
nomic structure of FGF14 was determined by aligning
cDNA (GenBank accesssion number NM_004115) to
genomic sequence (GenBank accesssion number NT_
009952). Primers were designed to amplify DNA from
coding regions, splice sites, and 50 bases of flanking
intronic sequence on both sides of each exon. Amplifi-
cation was performed with 10-min initial denaturation
at 94C; 35 cycles of 30-s denaturation at 94C, 30-s
annealing at 55C (for exons 2, 3, and 4), at 57C (for
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Figure 3 A, Sequence electropherograms of mutations found in FGF14. Both normal (left) and mutated (right) DNA and amino acid
sequences are shown. B (top), Amino acid sequence comparison of FGF11–FGF14 homologs in Homo sapiens, Mus musculus, and Gallus
gallus, showing the conservation of the amino acid mutated in FGF14 (F145S) in the family with ataxia. The change of a phenylalanine to a
serine in patients is indicated by an arrow. Only the alignment with amino acids 139–159 of FGF14 is shown. B (bottom), Amino acid sequence
comparison around the mutated F145S for all FGFs found in Homo sapiens. Amino acid alignments were performed with ClustalW.
exon 5), or at 61C (for exon 1), and 90-s extension at
72C; and 5-min final extension at 72C. Primer se-
quences and sizes of amplified fragments are listed in
table 2. PCR reactions for all exons were performed in
50 ml containing 10# PCR buffer (Gibco/Invitrogen);
1.5 mMMgCl2; 200 mMdNTP; 0.8 mM forward primer;
0.8 mM reverse primer; 2.5 U Taq polymerase (Gibco/
Invitrogen); and 50 ng genomic DNA. PCR products
were purified with the Amersham GFX-PCR, DNA, and
Gel Band Purification Kit, and their approximate con-
centration was determined by use of Low DNA Mass
Ladder (Gibco BRL). Sequencing reactions were essen-
tially performed as specified by the manufacturers, using
BigDye Terminator chemistry, version 1 (Applied Bio-
systems). Products were loaded on an ABI 3100 auto-
mated sequencer and analyzed with SeqScape (version
1.1) for heterozygous base calls and sequence alignment.
We identified a TrC transition at position 434 of the
FGF14a ORF in exon 4, resulting in an amino acid sub-
stitution of a serine for a phenylalanine at position 145
(F145S) (fig. 3A).
Testing of the base change in exon 4 on all available
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family members and 376 control chromosomes from the
general Dutch population was done with allele-specific
oligo hybridization; PCR products containing exon 4
were blotted ontoHybond-N (AmershamBiosciences).
The blots were hybridized for 1 h at 37C in 5# sodium
chloride sodium phosphate EDTA, 1% SDS, and 0.05
mg/ml single-strand salmon sperm DNA with either the
normal (tgcaagtttaaagaat) or mutated (tgcaagtctaaagaat)
sequence primer. Filters were washed to a final stringency
of 0.3# SSC, 0.1% SDS, at 37C. The base change in
exon 4 was not found in the general Dutch population,
and it segregates completely with the disease phenotype
in the family. No other sequence changes segregating
with the disease phenotype were identified. The individ-
ual (III:1) for whom diagnosis was uncertain did not
share the disease-associated haplotype and mutation.
To investigate the structural consequences of the
F145S mutation described here, the sequence of FGF14
was submitted to the 3D-PSSM (position-specific scoring
matrix) fold-recognition server (Kelley et al. 2000),
which identified six homologues of known structure
with E values ranging from 0.005 to 0.1. A molecular
model of FGF14 was built on the basis of the known
structure of human FGF9 (MIM 600921). The corres-
ponding structure of FGF9, solved by X-ray crystallo-
graphy at 2.6 A˚ resolution (Protein Data Bank entry
1G82), was therefore used as a modeling template
(Hecht et al. 2001). Side chains were built, usingWHAT
IF (Vriend 1990), and the model was then refined with
YASARA (Krieger et al. 2002). Validation of the model
with WHAT_CHECK (Hooft et al. 1996) showed struc-
ture Z scores in normal ranges, slightly better than those
of the template. The model coordinates are available on
request. With 39% sequence identity and an almost gap-
less alignment spanning 144 residues, both proteins can
be expected to adopt the same fold (Rost 1999). The
highest scoring alignment, with 39% sequence identity,
spanned residues Arg 63 to Tyr 206 and was gapless
except for a single one-residue insertion. In this model,
F145 is deeply buried and forms a central part of the
hydrophobic core. An in silico mutation to serine
showed that although its hydroxyl group can form a
hydrogen bond with the backbone oxygen of V114, the
now-missing bulky phenyl ring leaves a big space in the
protein’s core (fig. 3C). It is well known that mutations
leading to empty space in the core are very destabilizing
(De Vos et al. 2001), especially if the structure is rigid
and cannot easily accommodate the changes. We there-
fore conclude that the F145S mutation does not act di-
rectly, by influencing the interaction of FGF14with other
cellular factors, but most likely indirectly, by reducing
its stability.
The present study demonstrates for the first time that
a mutation in FGF14 is associated with autosomal dom-
inant cerebral ataxia with apparent complete pene-
trance. The FGF protein family currently consists of 23
known FGFs (Smallwood et al. 1996; ADHR Consor-
tium 2000; Ornitz and Itoh 2001). FGF11 through
FGF14 share !30% amino acid identity with other FGFs
but retain core conserved amino acid residues in exons
2, 3, and 4. However, FGF11 through FGF14 share
58%–71% amino acid sequence identity with each other,
lack a secretory sequence as seen in the other FGFs, and
are indeed not secreted in the medium of transfected cells
but accumulate to high levels intracellularly instead
(Smallwood et al. 1996;Wang et al. 2000). Furthermore,
no interaction with FGF receptors has been identified,
making it likely that their mechanism of function is dif-
ferent from the other FGFs.
The alternatively spliced exon 1 appears to encode
dominant protein-trafficking signals to target the pro-
teins to different subcellular compartments (Smallwood
et al. 1996; Munoz-Sanjuan et al. 2000; Wang et al.
2000); FGF14a is mainly located in the nucleus, whereas
FGF14b is located in the cytoplasm of transfected
NIH3T3 cells (Wang et al. 2000). In addition, in the
primary sequence, two nuclear-localization domains can
be predicted, (89-PSASRRR-95) and (122-KKRR-125).
Other functional motifs are a peroxisomal domain (125-
RLRRQDPQL-133) and an endoplasmatic reticulum
membrane domain (308-KSKT-311).
The expression pattern of Fgf14 in mice suggests a
role in both neuronal development and adult brain func-
tion. In embryonic mice at E12.5, the gene is expressed
in the ventral lining of the third and fourth ventricles of
the subventricular zone, which gives rise to neurons of
several brain regions, including the cerebellum. The gene
is also expressed in the supraoptic and septal areas, spi-
nal cord, and several nonneuronal tissues (Wang et al.
2000). Fgf14 is also expressed in the adult mouse brain,
with highest levels of expression in the granular cells of
the cerebellum and moderate to high levels in hippo-
campus in amygdala, cerebral cortex, striatum, and thal-
amus. A b-galactosidase reporter protein showed that
Fgf14 is mainly present in axons and almost entirely
absent in cell bodies.
Mutations in FGF genes are rare; only mutations in
FGF23 have been associated with autosomal dominant
hypophosphataemic rickets (ADHR Consortium 2000).
The F145S mutation in the present family with cerebellar
ataxia is the first genetic defect found in one of the
FGF11–FGF14 genes, encoding a subgroup of FGFs that
do not interact with FGF-receptor proteins. The F145S
mutation found in this family affects a highly conserved
amino acid and is located in a region of the proteinwhere
several other amino acids are conserved between FGFs
(for example, C143 is conserved in all FGFs; see fig. 3B).
The region of the protein is especially conserved in the
subgroup of FGF11–FGF14 (MIM 601514, 601513,
300070, and 601515), indicating that it might encode
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a domain that is specifically involved in the function of
this subgroup of FGFs. However, the exact effect of the
mutation on the function is difficult to predict, since very
little is known about the function of FGF14.
The clinical presentation of the F145S muta-
tion—tremor in childhood years, ataxia slowly progres-
sive over decades, with normal life expectancy in the
family we describe—was quite characteristic for this
SCA type. The absence of genetic anticipation and of
variation in clinical phenotype in the present family al-
ready made an expansion of a trinucleotide repeat un-
likely before identification of the F145S mutation. The
FGF14 gene is separated from the SCA8 locus by 30
cM on the sex-averaged linkage map (Koob et al. 1999).
However, the controversy over the causal relation be-
tween the expanded CTG repeat and SCA8 justifies
screening of the FGF14 gene in patients with SCA8 for
whom no linkage data excluding the current locus are
available (Juvonen et al. 2000; Vincent et al. 2000; Sob-
rido et al. 2001).
The phenotype of the F145S mutation in the present
family showed striking similarities with the findings of
ataxic gait, widened stance, lack of forefoot-hindfoot
correspondence, and paroxysmal hyperkinetic dyskine-
sia in homozygous Fgf14-knockout mice at age 3 wk
(Wang et al. 2002). The cerebellar ataxia in the present
patients with the F145S mutation may be caused by
dysfunction of cerebellar granule cells in the internal
granular layer, since FGF14N b-galactosidase staining in
transgenic mice was most intense in the molecular layer
where axons of granule cells extend. The findings in
patients with the FGF14 mutation and in the Fgf14-
knockout mice may suggest a dysfunction in the basal
ganglia circuitry. Fgf14 is not expressed by dopaminergic
neurons but in other neurons of the striatopallidal and
striatonigral pathways (Wang et al. 2002). The inability
to complete primary education, low cognitive perform-
ances, and aggressive outbursts in several of our patients
might reflect changes in the development and survival
of neuronal populations in the cerebral cortex, amyg-
dala, and basal ganglia. Fgf14 is localized in axonal pro-
jections, and it has been suggested that it plays a role
in axonal function, synaptosomal function, or neuro-
transmission (Wang et al. 2002). The question is whether
and how Fgf14 dysfunction represents a novel pathway
of neurodegeneration. It seems unlikely that intranuclear
inclusions, which are the pathological hallmarks of po-
lyglutamine disorders (Zoghbi et al. 1999), will be found
in the brains of patients with the F145S mutation, and
we need to wait for available postmortem tissue to in-
vestigate which cell type is primarily involved and to
determine the subcellular distribution of mutant FGF
protein. In addition, functional studies, using model sys-
tems, will be required to help solve these questions.
It is tempting to compare the available Fgf14 knock-
out model directly with the clinical phenotype in the
family described here, although we need to be cautious
since in the family we describe the trait segregates in an
autosomal dominant fashion. Each patient carrying the
mutant copy of the gene still has one fully functional
copy of the gene as well. However, because the F145S
mutation is located in the central core of the protein and
is likely to result in a decreased stability of the protein,
a loss of function of the protein is a more likely expla-
nation than increased aggregation properties of the pro-
tein. Expression studies using the mutant protein in
transgenic mice and cellular models may resolve this is-
sue in the near future. Since an animal model lacking
Fgf14 is available, it is therefore important to investigate
whether a heterozygous knockout mouse, which appears
to be normal at age 4 wk (Wang et al. 2000), does show
abnormalities when more-sensitive tests for motor and
coordination are applied or when tests are performed at
a later stage in life.
In conclusion, the pathogenic F145S mutation in the
FGF14 gene is a representative of a novel gene defect
for cerebellar ataxia. Mutational screening in familial
ataxia of unknown genetic cause, and in SCA8 in par-
ticular, will resolve the question of how frequent this
gene defect is. Pathologic examination of brain tissue
from ataxic patients with the F145S mutation and func-
tional studies using model systems may shed more light
on the normal function of FGF14 and characterize a
new pathway to neurodegeneration.
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